Go Pro
NASDAQ:XAGE

Longevity Health Q2 2025 Earnings Report

Longevity Health logo
$0.26 0.00 (0.00%)
As of 11:31 AM Eastern

Longevity Health EPS Results

Actual EPS
-$1.56
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Longevity Health Revenue Results

Actual Revenue
$0.50 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Longevity Health Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Longevity Health Earnings Headlines

Longevity Health (NASDAQ:XAGE) Shares Up 3.4% - Should You Buy?
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel
Longevity Health Holdings Ends Merger with True Health
Why Longevity Health Stock Is Skyrocketing Today
See More Longevity Health Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Longevity Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Longevity Health and other key companies, straight to your email.

About Longevity Health

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

View Longevity Health Profile